Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All famotidine studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/intubation 57% Improvement Relative Risk Famotidine for COVID-19  Freedberg et al.  Prophylaxis Is prophylaxis with famotidine beneficial for COVID-19? PSM retrospective 1,620 patients in the USA Lower death/intubation with famotidine (p=0.019) c19early.org Freedberg et al., Gastroenterology, May 2020 Favors famotidine Favors control

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Freedberg et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.053
May 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
PSM retrospective 1,620 hospitalized patients in the USA, 84 with existing famotidine use, showing lower risk of combined death/intubation with treatment.
risk of death/intubation, 57.0% lower, RR 0.43, p = 0.02, treatment 8 of 84 (9.5%), control 332 of 1,536 (21.6%), NNT 8.3, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Freedberg et al., 21 May 2020, retrospective, propensity score matching, USA, peer-reviewed, 15 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFamotidineAll
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
MD, MS Daniel E Freedberg, Joseph Conigliaro, Timothy C Wang, Kevin J Tracey, Michael V Callahan, MD, MS Julian A Abrams, Magdalena E Sobieszczyk, David D Markowitz, Aakriti Gupta, Max R O’donnell, Jianhua Li, David A Tuveson, Zhezhen Jin, William C Turner, Donald W Landry
Gastroenterology, doi:10.1053/j.gastro.2020.05.053
See Covering the Cover synopsis on page 803.
Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at https://doi.org/10.1053/ j.gastro.2020.05.053.
References
Anand, Ziebuhr, Wadhwani, None, Science
Bourinbaiar, Fruhstorfer, None, Life Sci
Chen, Deng, Churchill, None, Cell Stem Cell
Gottschlich, Delegge, Guenter, American Society for Parenteral and Enteral Nutrition
Li, Zhang, Liu, Gu, None, FASEB J
Wu, Liu, Yang, None, Acta Pharm Sin B
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit